Patents Assigned to Pfizer Inc.
  • COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR RESPIRATORY CONDITION MONITORING AND CARE
    Publication number: 20230329630
    Abstract: Technology is disclosed for monitoring a user's respirator), condition and provide decision support by analyzing a user's audio data. Spoken phonemes may be detected within audio data, and acoustic features may be extracted for the phonemes. A distance metric may be computed to compare phoneme feature sets of a user. Based on the comparison, a determination about the user's respiratory condition, such as whether the user has a respiratory condition (e.g., an infection) and/or whether the condition is changing, may be made. Some aspects include predicting the user's respiratory condition in the future utilizing the phoneme feature sets. Decision support tools in the form of computer applications or services may utilize the detected or predicted respiratory condition information to initiate an action for treating a current condition or mitigating a future risk.
    Type: Application
    Filed: August 30, 2021
    Publication date: October 19, 2023
    Applicant: PFIZER INC.
    Inventors: Shyamal Patel, Paul William Wacnik, Kara Chappie, Robert Mather, Brian Tracey, Maria del Mar Santamaria Serra
  • COMBINATION THERAPY
    Publication number: 20230321042
    Abstract: This invention relates to combination therapies for use in treating cancer, comprising a cyclin dependent kinase 2 (CDK2) inhibitor of Formula (I), as further described herein, and a cyclin dependent kinase 4/6 (CDK4/6) inhibitor, optionally in further combination with an additional anti-cancer agent=.
    Type: Application
    Filed: July 16, 2021
    Publication date: October 12, 2023
    Applicant: PFIZER INC.
    Inventors: Stephen George DANN, Nichol Lee Goodman MILLER, Todd Lee VANARSDALE
  • N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors
    Publication number: 20230322777
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Application
    Filed: May 3, 2023
    Publication date: October 12, 2023
    Applicant: Pfizer Inc.
    Inventors: Mary Theresa Didiuk, Robert Lee Dow, David Andrew Griffith
  • Substituted N-pyrimidin-4-yl-3-aminopyrrolo[3,4-C]pyrazoles as protein kinase C inhibitors
    Patent number: 11780853
    Abstract: The present invention relates to protein kinase C beta II inhibiting compounds of Formula (A): wherein A, B, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined herein. The invention further relates to pharmaceutical compositions comprising the compounds of Formula (A), or pharmaceutically acceptable salts thereof, and methods for treating a disease or disorder selected from the group consisting of Alzheimer's disease, cancer, a cardiovascular disease, a central nervous system disorder, depression, a dermatological disease, diabetes mellitus, a complication arising from diabetes mellitus, a disease in which the liver is a target organ inflammation, an inflammatory disorder, ischemia, and a viral disease.
    Type: Grant
    Filed: December 1, 2021
    Date of Patent: October 10, 2023
    Assignee: PFIZER INC.
    Inventors: Hui Li, Seiji Nukui, Stephanie Anne Scales, Min Teng, Chunfeng Yin
  • CD47 blockade therapy by HDAC inhibitors
    Patent number: 11779631
    Abstract: CD47+ disease cells such as cancer cells are treated using a combination of CD47 blockade drug and a histone deacetylase (HDAC) inhibitor. The anti-cancer effect of one drug enhances the anti-cancer effect of the other. Specific combinations include SIRP?Fc as CD47 blockade drug, and one of depsipeptide and romidepsin as HDAC inhibitor. These combinations are useful particularly to treat blood cancers including lymphomas, leukemias and myelomas.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: October 10, 2023
    Assignee: Pfizer Inc.
    Inventors: Emma Linderoth, Natasja Nielsen Viller, Robert Adam Uger, Penka Slavcheva Slavova-Petrova
  • Stable Topical Formulations of 1(R)-4-(5-(4-Methoxy-3-Propoxphenyl)Pyridin-3-YL)-1,2-OX-Aborolan-2-OL
    Publication number: 20230310472
    Abstract: The present invention relates to the discovery of chemically and physically stable topical formulations comprising (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (PF-07038124) for treating inflammatory disorders and to methods of preparing the topical formulations.
    Type: Application
    Filed: August 16, 2021
    Publication date: October 5, 2023
    Applicant: Pfizer Inc.
    Inventor: Thean Yeow Yeoh
  • CDK2 inhibitors
    Patent number: 11773082
    Abstract: This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.
    Type: Grant
    Filed: April 20, 2021
    Date of Patent: October 3, 2023
    Assignee: PFIZER INC.
    Inventors: Douglas Carl Behenna, Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Asako Nagata, Sacha Ninkovic, Scott Channing Sutton
  • CD47 blockade with radiation therapy
    Patent number: 11771764
    Abstract: This patent application relates to the treatment of cancer and other diseases that have a CD47+ phenotype. Treatment involves the use of radiation and a CD47-binding agent, preferably a CD47-binding form of human signal regulatory protein alpha (SIRPa) that inhibits activation of the CD47/SIRPa axis and mediates phagocytosis of CD47+ disease cells. An anti-cancer effect of a CD47 blocking agent is enhanced when combined with radiation therapy. The anti-cancer effect of a CD47 blocking agent such as SIRPaFc is enhanced when combined with radiation therapy.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: October 3, 2023
    Assignee: Pfizer Inc.
    Inventors: Lei Cui, Lisa Danae Schultz Johnson
  • METHODS, DOSAGE REGIMENS, AND COMPOSITIONS FOR TREATING HIDRADENITIS
    Publication number: 20230293544
    Abstract: There are methods, dosage regimens, and compositions for treating hidradenitis suppurativa.
    Type: Application
    Filed: March 8, 2023
    Publication date: September 21, 2023
    Applicant: PFIZER INC.
    Inventors: Brian Gerstenberger, Andrew Fensome, Dafydd Owen
  • Cells Having Gene Duplications and Uses Thereof
    Publication number: 20230287455
    Abstract: Host cells having improved growth characteristics are provided. Also provided are methods of selecting, using, and making the cells.
    Type: Application
    Filed: July 27, 2021
    Publication date: September 14, 2023
    Applicant: Pfizer Inc.
    Inventor: Lin Zhang
  • IMPROVEMENTS TO WASH SOLUTIONS FOR ANION EXCHANGE CHROMATOGRAPHY IN A METHOD OF PURIFICATION OF RECOMBINANTLY-PRODUCED RSV PROTEINS
    Publication number: 20230287041
    Abstract: The invention relates to a purification method of an RSV protein, wherein a load solution comprising the RSV protein is contacted with an anion exchange chromatography medium, whereby the RSV protein binds to the anion exchange chromatography medium, the anion exchange chromatography medium is washed with at least one wash solution and the RSV protein is eluted from the anion exchange chromatography medium.
    Type: Application
    Filed: July 22, 2021
    Publication date: September 14, 2023
    Applicant: Pfizer Inc.
    Inventors: Jill Ann PADDOCK, Alexandra PETTAWAY, Jeffrey Richard SALM
  • STABLE PHARMACEUTICAL TOPICAL FORMULATION CONTAINING IMMUNOSUPPRESSANT FOR TREATING DERMATOLOGICAL CONDITION
    Publication number: 20230277537
    Abstract: A stable, yellowing-resistant topical formulation for the treatment of a dermatological condition includes a JAK inhibitor in an oil-in-water emulsion; white petrolatum in an amount of about 10% by wt.; less than about 0.7 ppm butyl hydroxytoluene (BHT) by wt.; oleyl alcohol in an amount of about 2% by wt.; and an antimicrobial agent.
    Type: Application
    Filed: July 12, 2021
    Publication date: September 7, 2023
    Applicant: PFIZER INC.
    Inventors: Raymond Ruzhong Chen, Amanda Patrice Surajhie Samuel, Todd Christopher Zelesky, Xiang Zhang
  • Benzimidazole Derivative Compounds and Uses Thereof
    Publication number: 20230280220
    Abstract: The invention relates to benzimidazoles of Formula (1) and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (1) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.
    Type: Application
    Filed: April 17, 2023
    Publication date: September 7, 2023
    Applicant: Pfizer Inc.
    Inventors: Scott William Bagley, Agustin Casimiro Garcia, Xiayun Cheng, Jennifer Elizabeth Davoren, Rajiah Aldrin Denny, Brian Stephen Gerstenberger, Frank Eldridge Lovering, Mihir Dineshkumar Parikh, Joseph Walter Strohbach, John Isidro Trujillo
  • CD1a antibodies and uses thereof
    Patent number: 11746154
    Abstract: Antibodies, and antigen-binding fragments thereof, that specifically bind to Cluster of Differentiation 1a (CD1a) are provided. Embodiments include uses, and associated methods of using the antibodies, and antigen-binding fragments thereof.
    Type: Grant
    Filed: October 7, 2021
    Date of Patent: September 5, 2023
    Assignees: Pfizer Inc., Children's Medical Center Corporation
    Inventors: Florian Winau, Oleg V. Kovalenko, Chew Shun Chang, Di Wu, Nicholas Andrew Marze, Shian-Huey Chiang
  • SYSTEM AND METHOD FOR INFORMATION MANAGEMENT IN COMPUTERIZED INJECTORS
    Publication number: 20230263960
    Abstract: The invention relates to a computer-controlled injector, comprising: a housing configured to receive a medicament cartridge; an injection drive mechanism comprising a computer-controlled motor for driving a piston within said medicament cartridge, for injecting the medicament; a data tag attachable to said medicament cartridge; and an electromagnetic detector disposed within said housing and being connectable to the data tag upon mounting of said medicament cartridge into said housing, said electromagnetic detector permitting data to be read from or written to said data tag. The electromagnetic detector is configured to read or write data irrespectively of a rotational orientation of said medicament cartridge within said computer-controlled injector.
    Type: Application
    Filed: July 12, 2021
    Publication date: August 24, 2023
    Applicant: PFIZER INC.
    Inventor: Ozi BEN-ARI
  • Preparation Of A Pyrimidinyl-3,8-Diazabicyclo[3.2.1]Octanylmethanone Derivative And Salt Thereof
    Publication number: 20230265101
    Abstract: Methods for preparing ((S)-2,2-difluorocyclopropyl)-((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]-octan-8-yl)methanone and intermediates used in the processes of preparation thereof.
    Type: Application
    Filed: June 30, 2021
    Publication date: August 24, 2023
    Applicant: PFIZER INC.
    Inventors: Adam Edward GOETZ, Sally Gut RUGGERI, Robert Alan SINGER
  • compositions and methods thereof
    Patent number: 11730800
    Abstract: In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: August 22, 2023
    Assignee: Pfizer Inc.
    Inventors: Kathrin Ute Jansen, Annaliesa Sybil Anderson, Judith Absalon, Jose Miguel Aste-Amezaga, Johannes Frederik Beeslaar, David Cooper, John Erwin Farley, Leah Diane Fletcher, Shannon Lea Harris, Thomas Richard Jones, Isis Kanevsky, Lakshmi Khandke, Paul Liberator, John Lance Perez, Lynn Marie Phelan, Gary Warren Zlotnick
  • ENDOTOXIN DETECTION
    Publication number: 20230258664
    Abstract: Provided herein are methods and compositions for overcoming Low Endotoxin Recovery (LER) and unmasking endotoxins. The compositions and methods provided herein may be used to prepare samples such as drug products for endotoxin testing.
    Type: Application
    Filed: December 18, 2020
    Publication date: August 17, 2023
    Applicants: Pfizer Inc., Eli Lilly and Company
    Inventors: Matthew Christopher Bedwell, Ned Michael Mozier, Tammy Thurman, Robert Erwin Warburton, JR.
  • Glycoconjugation processes and compositions
    Patent number: 11723965
    Abstract: The invention provides eTEC linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: August 15, 2023
    Assignee: Pfizer Inc.
    Inventors: Jianxin Gu, Jin-hwan Kim, Avvari Krishna Prasad, Yu-ying Yang
  • CDK2 inhibitors
    Patent number: 11718603
    Abstract: This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.
    Type: Grant
    Filed: April 20, 2021
    Date of Patent: August 8, 2023
    Assignee: PFIZER INC.
    Inventors: Douglas Carl Behenna, Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Asako Nagata, Sacha Ninkovic, Scott Channing Sutton